SCHEMBL9635499

SCHEMBL9635499

CCC(COc1ccc(OCc2ccc3ccccc3n2)cc1COCc1ccc2c(c1)OC(c1nnn[nH]1)=CC2)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CYSLTR1 Q9Y271 9/20 0.40
PPARG P37231 1/20 0.35
CYSLTR2 Q9NS75 5/20 0.35
ALOX5AP P20292 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9635532 0.84 CYSLTR1 (0.40) CYSLTR1CYSLTR2
SCHEMBL9636824 0.74 CYSLTR1 (0.45) CYSLTR1CYSLTR2ALOX5AP
SCHEMBL9673252 0.73 CYSLTR1 (0.44) CYSLTR1CYSLTR2ALOX5AP
SCHEMBL9635637 0.72 CYSLTR1 (0.37) CYSLTR1CYSLTR2
SCHEMBL9637032 0.71 CYSLTR1 (0.46) CYSLTR1PPARGCYSLTR2ALOX5AP
SCHEMBL9757127 0.70 CYSLTR1 (0.46) CYSLTR1PPARGCYSLTR2ALOX5AP
SCHEMBL9757024 0.66 CYSLTR1 (0.42) CYSLTR1CYSLTR2
SCHEMBL9757216 0.66 CYSLTR1 (0.38) CYSLTR1CYSLTR2
SCHEMBL10544491 0.64 CYSLTR1 (0.66) CYSLTR1CYSLTR2
SCHEMBL9818468 0.63 CYSLTR1 (0.56) CYSLTR1CYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5082849-A Antiinflammatory agents or antiallergens AVENTIS PHARMACEUTICALS INC. 1992-01-21 US disclosed
EP-0434827-A1 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-07-03 EP disclosed
WO-1991001123-A2 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? RORER INTERNATIONAL (OVERSEAS) INC. (US) 1991-02-07 WO disclosed
US-4977162-A Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments RORER PHARMACEUTICAL CORPORATION (US) 1990-12-11 US disclosed